tiprankstipranks
Advertisement
Advertisement

ASND Stock Latest News

Analyst Reiterates Buy on Ascendis Pharma, Keeps $288 Price Target Amid ITC Uncertainty and Strong Yorvipath Rollout
RatingsAnalyst Reiterates Buy on Ascendis Pharma, Keeps $288 Price Target Amid ITC Uncertainty and Strong Yorvipath Rollout
3d ago
ASND
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
PremiumThe Fly
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
15d ago
AMT
BAP
Ascendis Pharma initiated with a Buy at Citi
PremiumThe Fly
Ascendis Pharma initiated with a Buy at Citi
16d ago
ASND
Ascendis Pharma price target raised to $329 from $324 at Evercore ISI
PremiumThe Fly
Ascendis Pharma price target raised to $329 from $324 at Evercore ISI
19d ago
ASND
Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants
PremiumCompany Announcements
Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants
21d ago
6K
ASND
Ascendis Pharma price target raised to $345 from $342 at Barclays
PremiumThe FlyAscendis Pharma price target raised to $345 from $342 at Barclays
24d ago
ASND
Ascendis Pharma Earnings Call Highlights Growth Momentum
Premium
Company Announcements
Ascendis Pharma Earnings Call Highlights Growth Momentum
24d ago
ASND
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo
Premium
The Fly
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo
27d ago
ASND
Analyst Reiterates Buy on Robust Rare Endocrine Portfolio and Pipeline Progress as Price Target Nudged to $288 on Higher Share Count
PremiumRatings
Analyst Reiterates Buy on Robust Rare Endocrine Portfolio and Pipeline Progress as Price Target Nudged to $288 on Higher Share Count
27d ago
ASND
Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15)
PremiumThe Fly
Ascendis Pharma reports Q1 adjusted EPS EUR 0.29, consensus EUR (0.15)
27d ago
ASND
Ascendis Pharma Swings to €629 Million Q1 2026 Profit on Strong Revenue Growth
PremiumCompany Announcements
Ascendis Pharma Swings to €629 Million Q1 2026 Profit on Strong Revenue Growth
27d ago
6K
ASND
Ascendis Pharma Q1 2026 Results Highlight YORVIPATH Growth and U.S. Launch of YUVIWEL
PremiumCompany Announcements
Ascendis Pharma Q1 2026 Results Highlight YORVIPATH Growth and U.S. Launch of YUVIWEL
27d ago
6K
ASND
Ascendis Pharma Calls Full Redemption of $575 Million 2028 Convertible Notes After Share Price Surge
PremiumCompany AnnouncementsAscendis Pharma Calls Full Redemption of $575 Million 2028 Convertible Notes After Share Price Surge
1M ago
6K
ASND
Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares
Premium
Company Announcements
Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares
1M ago
6K
ASND
Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading
Premium
Company Announcements
Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading
1M ago
6K
ASND
Ascendis Pharma announces commencement of trading of shares on Nasdaq
PremiumThe Fly
Ascendis Pharma announces commencement of trading of shares on Nasdaq
1M ago
ASND
Ascendis Tracks YORVIPATH in Breast Milk: What Investors Should Know
PremiumCompany Announcements
Ascendis Tracks YORVIPATH in Breast Milk: What Investors Should Know
2M ago
ASND
2 Best ETFs to Buy in April 2026, According to Analysts
PremiumMarket News
2 Best ETFs to Buy in April 2026, According to Analysts
2M ago
LLY
ABBV
Ascendis Pharma price target raised to $292 from $262 at BofA
PremiumThe Fly
Ascendis Pharma price target raised to $292 from $262 at BofA
2M ago
ASND
Ascendis Pharma Issues New Employee Warrants as Part of Long-Term Incentive Program
PremiumCompany AnnouncementsAscendis Pharma Issues New Employee Warrants as Part of Long-Term Incentive Program
2M ago
6K
ASND
Ascendis Pharma Reports Strong Week 52 COACH Trial Data for TransCon CNP and hGH Combo in Achondroplasia
Premium
Company Announcements
Ascendis Pharma Reports Strong Week 52 COACH Trial Data for TransCon CNP and hGH Combo in Achondroplasia
2M ago
6K
ASND
Ascendis Pharma to Replace ADSs With Direct Ordinary Share Listing on Nasdaq
Premium
Company Announcements
Ascendis Pharma to Replace ADSs With Direct Ordinary Share Listing on Nasdaq
2M ago
6K
ASND

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >